Antibody-drug conjugates (ADCs) represent a cutting-edge advancement in cancer therapy. These unique biopharmaceuticals act as "smart bombs," combining monoclonal antibodies specifically targeting cancer cells with potent cytotoxic drugs delivered directly to the tumor site. This precise targeting reduces collateral damage to healthy cells, minimizing adverse effects.
Given the growing adoption of ADCs in clinical oncology, predicting their efficacy has become a critical challenge. Factors such as tumor heterogeneity, antigen expression, and individual patient differences underscore the need for precise biomarkers and advanced tools to determine patient suitability. The integration of immunohistochemistry (IHC) and next-generation sequencing (NGS) has emerged as a powerful approach to refining this prediction process.
This blog explores the challenges of predicting ADC efficacy, the roles of IHC and NGS, and how these technologies are shaping the future of ADC-based therapy.
The Importance of Predicting ADC Efficacy
Why Predicting ADC Outcomes is Crucial?
The therapeutic landscape of ADCs continues to evolve, with several FDA-approved ADCs and many others progressing through clinical trials. However, not all patients with cancer respond to these therapies, making the prediction of ADC efficacy vital to ensuring optimal outcomes. Key considerations include:
• Target Antigen Expression: ADCs' performance depends on the presence and density of specific antigens on tumor cells.
• Tumor Heterogeneity: Variability in antigen expression within and between tumors can impact ADC penetration and effectiveness.
• Resistance Mechanisms: Both primary and acquired resistance to ADCs challenge their sustained efficacy.
The Role of Immunohistochemistry in Predicting ADC Efficacy
How IHC Works in ADC Therapy?
Immunohistochemistry (IHC) is a gold standard for detecting protein expression within tumors. By applying antigen-specific antibodies to tissue samples, IHC enables visualization and quantification of target antigens. For ADCs, this method is highly valuable in determining whether a patient’s tumor expresses the antigen necessary for ADC binding and delivery.
Benefits of Using IHC for ADC Target Assessment
Challenges in IHC Analysis
Quantification of protein expression in IHC is typically assessed with H-scores, calculated by pathologists based on the identification of the percentage of cancer cells expressing the target and its level of intensity. The subjectivity of the methodology is an inherent risk of inconsistency for inter- intra- assay, for this reason, the H-score is usually calculated as the result of the independent IHC data analysis from at least two pathologists. Also, despite its benefits, IHC has limitations in predicting ADC efficacy, as for known ADC targets such as HER2 and TROP2, the correlation between target expression-related IHC scores and ADC efficacy, is not always strong.
Next-Generation Sequencing (NGS) Contributions to ADC Accuracy
What is NGS and How it enhances ADC Targeting?
Next-generation sequencing (NGS) analyzes DNA, RNA, and gene expression at unprecedented speed and precision. By providing data-rich insights, NGS enables oncology researchers to evaluate molecular profiles in addition to traditional methods like IHC. In particular, NGS data can help researchers with the identification of biomarkers that may predict ADC responses. Recent studies have demonstrated NGS's advantages in ADC biomarker identification. For example, RNA sequencing correlations with IHC staining (e.g., TROP2, HER2) highlight strong alignment in certain targets, offering the potential for RNA-based cutoffs to complement IHC in ADC prediction. Variability, however, remains for some antigens, underscoring the need for continuing refinement.
Innovations in Predicting ADC Efficacy
Beyond IHC and NGS
Emerging technologies and methodologies are refining ADC efficacy prediction even further. Key innovations include:
• Multivariate Biomarkers: Next-gen tools like ADC Treatment Response Scores (ADC-TRS) evaluate gene expression alongside additional factors (e.g., adhesion, proliferation markers), significantly enhancing response prediction.
• AI-Powered Pathology: Artificial intelligence in cancer pathology is enabling automated image and molecular data analysis, providing deeper insights into tumor heterogeneity and antigen expression thresholds.
• Molecular Imaging: Imaging technologies are being integrated with NGS and IHC to provide real-time visualization of ADC biodistribution within patient tumors.
Future Potential
• Predictive Precision: Enhanced tools and algorithms will improve patient stratification, leading to better survival outcomes and fewer treatment-related toxicities.
• Adaptive Therapies: With the ability to monitor antigen dynamics over time, clinicians can tailor ADC therapies to evolving tumor characteristics.
Accurate Predictions Mean Better Outcomes for Patients
Antibody-drug conjugates are paving the way for highly targeted and effective cancer treatments. However, maximizing their potential hinges on the ability to accurately predict suitable candidates through methods like IHC and NGS.
By leveraging the latest advancements in predictive biomarkers and sequencing technologies, scientists and oncologists can improve patient outcomes, advancing precision medicine to new heights.
As the field evolves, innovations will continue to refine ADC efficacy predictions, enabling personalized treatment strategies that benefit patients across diverse cancer types.
Reach out to Champions Oncology to learn more about how we can help you develop your ADCs with our cutting-edge ex vivo and in vivo platforms and predictive tools that drive innovation.
[1] Katrini J, Boldrini L, Santoro C, Valenza C, Trapani D, Curigliano G. Biomarkers for Antibody-Drug Conjugates in Solid Tumors. Mol Cancer Ther. 2024 Apr 2;23(4):436-446. doi: 10.1158/1535-7163.MCT-23-0482. PMID: 38363729.
[2] Sachdev P. Thomas, Laurel A. Habel, Jennifer Marie Suga, Ninah Achacoso, Josh Nugent, Katarina M. Robinson, Ryan White, and Scott A. Tomlins. Evaluation of a predictive biomarker for antibody drug conjugates (ADCs). Journal of Clinical Oncology, Volume 42, Number 16_suppl. doi.org/10.1200/JCO.2024.42.16_suppl.3140
[3] Makawita S, Meric-Bernstam F. Antibody-Drug Conjugates: Patient and Treatment Selection. Am Soc Clin Oncol Educ Book. 2020 Mar;40:1-10. doi: 10.1200/EDBK_280775. PMID: 32213087.
[4] Kushnarev V, Stupichev D, Kryukov K, et al143 Correlating RNA-seq detection and IHC staining of potential antibody-drug conjugate (ADC) targets: HER3, HER2, TROP2, Nectin4, and aFLRJournal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.0143
[5] Ascione L, Crimini E, Trapani D, Marra A, Criscitiello C, Curigliano G. Predicting Response to Antibody Drug Conjugates: A Focus on Antigens' Targetability. Oncologist. 2023 Nov 2;28(11):944-960. doi: 10.1093/oncolo/oyad246. PMID: 37665782; PMCID: PMC10628585.
[6] Paolo F. Caimi, Mehdi Hamadani, Carmelo Carlo-Stella, Masoud Nickaeen, Eric Jordie, Kiersten Utsey, Tim Knab, Francesca Zammarchi, Serafino Pantano, Karin Havenith, Ying Wang, Joseph Boni; CD19 Expression by IHC Alone Is Not a Predictor of Response to Loncastuximab Tesirine: Results from the LOTIS-2 Clinical Trial and Quantitative Systems Pharmacology Modeling. Blood 2022; 140 (Supplement 1): 9548–9550. doi: https://doi.org/10.1182/blood-2022-159626